[1] Liaw YF,Leung N,Kao JH,et al.Asian-pacific consensus statement on the management of chronic hepatitis B:a 2008 update.Hepatol Int,2008,2（3）:263-283.
[2] Florian B,Mabnaz A,Francesco N,et al.The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physicans. Swiss Med Weekly,2010,140（11-12）:154-159.
[3] 中华医学会传染病与寄生虫病学分会和肝病学分会.病毒性肝炎防治方案. 中华肝脏病杂志,2000,8（6）：324-329.
[4] Fontana RJ.Management of patients with decompensated HBV cirrhosis. Semin Liver Dis,2003,23:89-100.
[5] Hann HW,Fontana RJ,Wright T,et al. A United States compassionate ues study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl,2003,9:49-56.
[6] Lee JM,Park JY,Kim DO Y,et al. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther,2010,15（2）:235-241.
[7] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[8] Fung SK,Lok AS. Management of hepatitis B patients with antiviral resistance.Antivir Ther,2004,9:1013-1026.
[9] Peters MG,Hann HW,Martin P,et al.Adefovir dipivoxil alone or in combination with lamivudine-resistant chronic hepatitis B. Gastroentreology.2004;126:91-101.
[10] 蒋晔,徐志儒,张晓青. 乙型肝炎新药阿德福韦酯的研究进展. 中国新药与临床杂志,2004,23：373-377.
[11] 王宇明,陈耀凯,张大志,等. 阿德福韦酯治疗拉米夫定耐药慢性乙型肝炎的临床研究. 中华肝脏病杂志,2006,14：803-805.
[12] Lampertico P,Vigano M,Manenti E,et al.Low resistance to adefovir combined with lamivudine:a 3-year study of 145 lamivudine-resistant hepatitis B patient. Gastroenterology,2007,133:1445-1451. |
